Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S is dated September 7, 2026. The report details the company's ongoing share repurchase programme initiated on May 6, 2026, under the EU Market Abuse Regulation (MAR). Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries.
Key Financial Metrics and Capital Allocation
The filing focuses on capital allocation via share buybacks rather than operational financial performance metrics such as revenue or profit.
- Total Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period beginning February 4, 2026.
- Specific Programme (May 6, 2026): Up to DKK 11,200,000,010.45 for B shares.
- Accumulated Repurchases (as of Sept 4, 2026): 32,034,179 B shares purchased since February 4, 2026.
- Total Value Repurchased (since Feb 4, 2026): DKK 9,021,774,283.
- Average Purchase Price (since Feb 4, 2026): DKK 281.63 per B share.
- Treasury Shares Held: 46,074,876 B shares (1.0% of total share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Material Changes and Recent Activity
Since the last announcement on August 31, 2026, the company executed the following transactions:
| Date | Shares Purchased | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| Sept 1, 2026 | 210,000 | 291.92 | 61,302,771 |
| Sept 2, 2026 | 215,000 | 293.94 | 63,196,785 |
| Sept 3, 2026 | 215,000 | 297.42 | 63,945,131 |
| Sept 4, 2026 | 200,000 | 300.03 | 60,006,094 |
The average purchase price in early September (approx. DKK 295-305) was higher than the programme average of DKK 281.63.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period starting February 4, 2026. As of September 4, 2026, approximately DKK 5.98 billion remains available under the total programme cap.
Risks and Contingencies: The filing does not disclose specific operational risks or contingencies. It notes that transaction details are published on the company website.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the remaining capacity of the DKK 15 billion share repurchase programme (approx. DKK 5.98 billion remaining as of Sept 4, 2026).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 291-305.
- Review the company's latest Form 20-F or quarterly report for operational revenue and profit data, as this 6-K contains only capital allocation data.
- Monitor the total treasury share count (currently 1.0% of share capital) for potential dilution or earnings per share impacts.